This study investigates the vasomotor activities of prostaglandin (PG) D2 in bovine coronary arteries in relation to endothelial function. Isolated segments of bovine coronary arteries with intact endothelium were concentration-dependently relaxed by PGD2 (0.01-1 ,uM), a reaction that was blocked by a selective PGD receptor antagonist (BW A868C). There was a tight correlation between PGD2-and acetylcholineinduced relaxations (r=0.894, n=96, p<0.001). Removal of endothelium abolished the PGD2-induced relaxation and unmasked a contractile activity of the compound. Inhibition of endogenous PGI2 formation by indomethacin did not modify these responses, whereas inhibition of endogenous nitric oxide generation by NG-nitro-L-arginine and NG_monomethyl L-arginine (10 or 100 ,uM) or scavenging of released nitric oxide by oxyhemoglobin (3 ,uM) considerably (>50%o) antagonized the PGD2-induced relaxation. The vessel relaxation by PGD2 was associated with a threefold to fourfold increase in vascular cGMP. A considerable reduction in vascular cGMP was measured after removal of the endothelium (by 53%) and inhibition of endogenous nitric oxide generation by NG-nitro-L-arginine (by 70%o). This also resulted in a complete inhibition of PGD2-induced cGMP accumulation. Similar results were obtained with the stable PGD2 mimetic ZK 110.841, suggesting that these biological activities of PGD2 were due to the compound itself and not caused by any PGD2 metabolite. A slight but significant increase in cAMP was observed in arteries with intact endothelium as well as after removal of endothelium. Because the relaxing effect of PGD2 was strictly endothelium dependent, the observed relaxation cannot be explained by cAMP. These data demonstrate a receptor-mediated, endothelium-dependent, nitric oxide-mediated, and cGMPmediated vessel relaxation by PGD2. (Circulation Research 1992;71:1305-1313 
(PGJ2). In contrast to other prostaglandins, these primary metabolites of PGD2, i.e., 9a-ll3-PGF2a and PGJ2, are biologically active and probably involved in the effects of PGD2.'2 Thus, biological activities of PGD2 in vivo are complex and, in general, difficult to assess because of unknown contributions of PGD2 metabolites.
In addition to species-dependent differences in PGD2 metabolism by vascular tissue,26 the involvement of different receptor (sub)types may also cause different vasomotor effects. By comparing the biological activity of PGD2 and a number of analogues on several target tissues, three different groups of PGD2-sensitive systems were identified.8 In general, the PGD receptor is assumed to mediate the inhibitory effects of PGD2, e.g., inhibition of platelet function, whereas the vascular ment of endothelium. No systematic investigation with PGD2 on this issue has been published so far. The aim of the present study was to determine the possible involvement of endothelium-derived mediators in the vasomotor actions of PGD2 in isolated coronary arteries. The possible involvement of nonprostanoid endothelium-derived vasoactive mediators, i.e., endothelium-derived relaxing factor or nitric oxide (NO),9"10 was analyzed by comparing the PGD2-induced relaxation with that evoked by acetylcholine (ACh), which is known to exert an endothelium-dependent cGMP-mediated relaxation of this tissue." In addition, selective NO synthase inhibitors and oxyhemoglobin (HbO2), a NO-scavenging agent, were used. The possible involvement of endogenous PGI was assessed by indomethacin. Finally, cellular signal transduction pathways were analyzed by determination of cyclic nucleotides cGMP and cAMP. To clarify the possible contribution of PGD2 metabolites, 9-deoxy-9,3-chloro-16,17,18,19,20-pentanor-15-cyclohexyl-PGF2a (ZK 110.841), a PGD2 agonist with high affinity to the PGD receptor,'2 was also included in the study.
The involvement of different receptors in the vascular effects of PGD2 was evaluated using BW A868C, a selective PGD receptor antagonist, and SQ 29.548, a selective thromboxane receptor antagonist. 13 
Materials and Methods Experimental Model
Coronary arteries were prepared from fresh bovine hearts that were obtained from a local slaughterhouse. Branches of the left coronary artery (ramus interventricularis and ramus circumflexus) were helically cut into strips (4x35 mm) and mounted in a 10-ml organ bath at a preload of 20 mN. The bath contained Krebs-Henseleit buffer (at 37°C and pH 7.4) supplemented with glucose (5 mM). The buffer was equilibrated with 20% 02-5% C02-75% N2, resulting in a Po2 of approximately 160 mm Hg in the bath fluid. Changes in the length of the vessels were measured isotonically with mechanoelectrical transducers (Fleck, Mainz, FRG) and were continuously registered on a multichannel recorder (Watanabe Mark VII, HSE, Freiburg, FRG). 
Validation of Endothelial Function

Statistics
Data are mean+SEM of n observations. Relaxing effects were quantitated in percentage of 5 -HT-induced contraction (0% relaxation). In experiments without precontraction, the active basal tone was set at 0% relaxation. Statistical evaluation was performed with the two-tailed t test. Values of p<0.05 were considered significant.
Results
Endothelium-Dependent Coronary Artery Relaxation by PGD2
Addition of 5-HT (1 ,uM) to vessel preparations caused a long-lasting contraction. This effect was independent of the presence of endothelium. Addition of ACh (0.01-10 ,uM) to these precontracted coronary artery segments resulted in a concentration-dependent vessel relaxation. PGD2 (0.01-1 ,uM) also caused a concentration-dependent and finally complete relaxation of coronary vessels with intact endothelium. Removal of the endothelium abolished the relaxing effects of both ACh and PGD2. In contrast, removal of the endothelium did not affect the relaxing effects of iloprost. These findings are exemplified in the original experiment shown in Figure 1 .
There was a tight linear correlation between maximum ACh-induced relaxation and maximum coronary relaxation induced by PGD2 (1 ,M) ( Figure 2 ). Complete relaxation (101+5%, n = 16) by PGD2 was found in preparations responding with >50% relaxation to ACh (maximal effective concentration, usually 1 ,M). This response was reduced to 45+5% in preparations relaxed by 20-45% by ACh (n=7). In preparations in which endothelium has been deliberately denuded, the relaxing effect of ACh as well as PGD2 was almost complete abolished (0.4±0.4%, n=14).
An endothelium-dependent relaxation by ACh and PGD2 was also obtained in coronary arteries at basal tone without addition of 5-HT. In the absence of endothelium, PGD2 (1 uM) exerted a contractile effect, amounting to 40±10% of the 5-HT-induced (100%) contraction (n = 4). These findings are exemplified in the original experiment shown in Figure 3 .
Effects of Inhibition of Prostacyclin Synthesis
The relaxing effect of PGD2 in preparations with intact endothelium remained unchanged in the presence of indomethacin. The PGD2 (1 ,uM)-induced relaxation amounted to 90+5% of control in the absence and 81+3% of control in the presence of indomethacin (n= 10, p>0.05).
Effects of Inhibition of Nitric Oxide Generation
Pretreatment of the vessels with the NO synthase inhibitors L-NMMA10 and L-NO2ARG16 resulted in a considerable attenuation of the relaxing effects of PGD2. L-NMMA (100 ,uM) and L-NO2ARG (100 ,uM) ACh-induced relaxation [%] inhibited the maximum PGD2 (1 ,uM)-induced relaxation by more than 60%. This effect was more prominent at lower concentrations of PGD2 (Table 1 ). In addition, the inhibition of PGD2 (0.01-1 gM)-induced relaxation by L-NO2ARG (10 ,uM) was antagonized by a fivefold excess of L-arginine (50 ,uM). There was again a clear concentration-response relation for both agonists and antagonists (Table 2) . In comparison, maximum ACh-induced relaxation was reduced from 76+5% in the absence to 21±+6% (n=9) in the presence of L-NO2ARG (100 ,M, p<O.05).
Effects of HbO2
Results similar to NO synthase inhibition were obtained after addition of HbO2 to the organ bath. This resulted in a further increase (36+7%) in vessel tone of 5-HT-contracted coronary arteries. In addition, HbO2 significantly reduced the relaxing effects of PGD2 (1 ,uM), amounting to 109+5% in the absence and 43±2%
in the presence of HbO2 (n=6, p<0.05). An even stronger inhibition was obtained at lower concentrations of PGD2. For example, 0.1 ,uM PGD2 relaxed the vessels by 70+7% of control but only by 11+2% in the presence of HbO2 (n=6, p<0.05). These findings are exemplified in the original tracing shown in Figure 4 .
In comparison, maximal ACh-induced relaxation was reduced from 84+5% in the absence to 23±3% (n=8) in the presence of HbO2 (3 ,uM). Actions of PGD2 and ZK 110.841 on Vascular cGMP Basal cGMP levels in coronary arteries amounted to 50±8 pmol/g wet wt in the absence (n=3) and 246±83 pmol/g wet wt in the presence of IBMX (n =8, p<0.05), confirming a significant cGMP-related phosphodiesterase activity in this tissue.1"14 All further experiments were therefore performed in the presence of IBMX.
The cGMP levels were unchanged by 5-HT (1 ,uM), amounting to 269±44 pmol/g wet wt (n=10, p>0.05). Mechanical removal of the endothelium or addition of L-NO2ARG reduced basal cGMP levels by 50-70%.
Addition of SIN-1 (100 ,mol/l) caused an 11-fold increase of cGMP to 2,966+528 pmol/g wet wt (p<0.01, n=8), whereas ACh (10 ,uM) stimulated cGMP to 985 ±204 pmol/g wet wt (n=6). In contrast to ACh, this action of SIN-1 was maintained after removal of the endothelium (data not shown). These data demonstrate a functionally active guanylate cyclase in the vessel preparations1"14 and the absence of specific stimulation by 5-HT at the concentrations used to contract the vessels.
Addition of PGD2 at 1 ,uM, the concentration that elicited maximum vessel relaxation, stimulated cGMP levels threefold to fourfold above control, i.e., to (Table 3) .
Actions of PGD2 on Vascular cAMP
Under control conditions, cAMP levels in coronary arteries with intact endothelium amounted to 4.7+0.2 nmol/g wet wt (n=7). PGD2 concentration-dependently enhanced cAMP levels. The increase, however, was considerably lower than after the addition of isoprenaline or iloprost. In these experiments cGMP levels were also significantly enhanced by PGD2, whereas isoprenaline and iloprost did not change cGMP levels (data not shown).
After removal of endothelium, basal cAMP levels were somewhat lower but stimulated by all three agents to a similar extent (Table 4) . Effects of PGD2 on cGMP, however, were abolished after removal of endothelium (data not shown).
Receptors Involved in the Vascular Effects of PGD2
The endothelium-dependent relaxation of bovine coronary arteries by PGD2 was concentration-dependently inhibited by BW A868C, a selective PGD receptor antagonist (Table 5, Figure 4) . BW A868C at higher concentrations (0.1 ,uM) completely abolished any relaxing effects of PGD2 and unmasked a contractile effect of PGD2 (15±1% of 5-HT contraction, n=5).
The contractile effect of PGD1 (10 ,uM) on basal tone of coronary arteries after endothelium removal amounted to 74+5% of maximal KCl (40 mM)-induced contraction.
BW A868C (>30 ,M) had no effect on these contractions. The contraction was concentration-dependently antagonized by SQ 29.548, a selective thromboxane receptor antagonist. The IC50 amounted to 76+10 nM (n =6, graphically determined).
Neither BW A868C nor SQ 29.548 had any direct effect on bovine coronary arteries in the concentrations used.
Discussion
This study demonstrates for the first time an endothelium-dependent cGMP-mediated relaxation of an isolated vessel preparation by a cyclooxygenase metabolite of arachidonic acid, i.e., PGD2. The following findings suggest that this response is due to a receptormediated endothelium-dependent NO release: 1) Known NO scavengers and inhibitors of endogenous NO biosynthesis inhibit the PGD2-induced relaxation. The cGMP levels in this study were somewhat higher than those in previous reports on bovine coronary arteries. This may be explained by differences in the experimental protocols. Alternatively, most if not all of the previous investigations were performed in bath media saturated with 95% oxygen.5 '7'11" 4 This results in P02 levels in the bath fluid of approximately 600 mm Hg. High oxygen partial pressure will facilitate generation of oxygen-centered free radicals, which in turn may inactivate endothelium-derived relaxing factor. 17 In this study, we have used 20% oxygen, resulting in Po2 values of 150-200 mm Hg. Kalsner22 has shown that only Po2 levels of 112 mm Hg and less will cause some hypoxiainduced relaxation of bovine coronary arteries, which involves release of vasodilating prostaglandins. In our hands, there was no evidence for any time-dependent decrease in vessel tone and, importantly, no specific effect of indomethacin at a concentration that has previously been shown to block PGI2 generation in this system. 23 Furthermore, the combined use of SOD and catalase did not alter the vascular response to PGD2. These data probably exclude an inactivation of extracellular NO (which can be scavenged by HbO2) by reactive oxygen species.17 On the other hand, the question arises of whether Po2 levels above 600 mm Hg may modify NO-related responses in isolated vessel preparations by creating an unphysiological hyperoxia.
Another explanation for the failure of SOD to enhance endothelium-dependent relaxation is the close contact between endothelial cells and vascular smooth muscle cells. Under these conditions, the amount of luminally released NO is probably very small. Additionally, a recent report demonstrated that the CuZn-SOD isoenzyme lacks affinity toward heparan sulfate and does not bind to cell surfaces, in contrast to human recombinant SOD type C. 24 It is generally accepted that cAMP is the second messenger of PGI2 in platelets and, eventually, other target cells. The inhibitory actions of PGD2 on platelets, mast cells, adipocytes, keratinocytes,2 polymorphonuclear cells,25 and several tissues, including rabbit transverse stomach strips,8 are also considered to be cAMP mediated.2 The PGD2 analogue ZK 110.841 was also found to stimulate cAMP levels in platelets'2 and polymorphonuclear cells25 at concentrations that inhibited cell function. The data in this study suggest that cAMP is not involved in PGD2-induced endothelium-dependent relaxation of bovine coronary arteries. Two lines of evidence support this statement: 1) There was no modification of PGD2 (1 ,uM)-induced vessel relaxation by indomethacin.
2) The small but significant stimulation of cAMP by PGD2 was also detectable after removal of endothelium. Under these conditions no relaxing effect of PGD2 was observed.
There is one previous study that reported an endothelium-dependent component in PGI2-induced relaxation of porcine coronary arteries that was abolished by HbO2. Because of similar vascular responses to forskolin, the authors concluded that this action of PGI2 was cAMP mediated.26 However, the evidence was indirect, and no measurements of cyclic nucleotides had been performed. Interestingly, in contrast to all other coronary arteries studied so far, PGI2 has been shown in an earlier report to contract coronary arteries of the pig.27
There is some evidence for interactions between lipoxygenase metabolites of arachidonic acid and cGMP-generating systems. Endothelium-dependent relaxations of rat aorta28 and canine superior mesenteric artery29 by cysteinyl leukotrienes have been reported as well as an increase in the vascular cGMP level by leukotriene D4. 29 The relaxing effect could be blocked by addition of HbO2,28 suggesting that endogenous NO generation was involved. A recent study has shown that 12-hydroperoxyeicosatetraenoic acid inhibited human platelet function by activation of soluble guanylate cyclase.30 Our results add further evidence to a possible interaction between arachidonic acid and NO pathways and extend the data on lipoxygenase-derived products to the cyclooxygenase product PGD2.
In conclusion, we have demonstrated an endothelium-dependent, endothelium-derived relaxing factor/ NO-stimulated, cGMP-mediated, relaxing effect of PGD2 in bovine coronary arteries. In addition, there is also a PGD2-induced vasoconstriction of coronary smooth muscle that is obviously mediated by thromboxane receptors. There is no evidence for a functional relevance of vascular and/or endothelial cAMP as a mediator of vessel relaxation induced by PGD2 in this system.
